(Gestational Trophoblastic Tumor) Is Anti-PD-1 Camrelizumab Plus Apatinib Effective?

• November 2, 2021
• 1 min read

On October 5, 2021, Dr. Hongyan Cheng and colleagues from Peking Union Medical College Hospital published results in The Lancet from a Phase 2 clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody camrelizumab combined with apatinib in patients with high-risk, chemotherapy-resistant, recurrent gestational trophoblastic tumors (GTT).

This Phase 2 trial was a single-arm, open-label study with a 4-week treatment cycle. Patients with high-risk, chemotherapy-resistant, recurrent GTT received camrelizumab (200 mg on days 1 and 15) plus apatinib (250 mg once daily) until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR).

Results at median follow-up of 18.5 months:

• Objective response rate (ORR): 55%
• Complete response (CR): 50%

Safety:

Grade 3 or higher adverse events observed in most patients included hypertension (25%, N=5), skin abnormalities (20%, N=4), and neutropenia (10%, N=2). No higher-grade adverse events were confirmed.

Conclusion: Based on the Phase 2 trial results, Dr. Cheng and colleagues concluded that camrelizumab plus apatinib demonstrated meaningful anti-tumor activity with acceptable tolerability in high-risk, chemotherapy-resistant, recurrent GTT patients, and may represent a new treatment option for this patient population.

Source: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00460-5/fulltext

• Immunotherapy

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4